ZLZihan Li

Zihan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zihan Li has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Genetic Drivers and Therapeutic Vulnerabilities of Metastatic Breast Cancer

    by Teng Fei, You Li, Shixin Ma, Zitao Xu, Xiaofeng Wang, Ruipu Liang, Zihan Li, Zexu Li, Yingjia Yao, Weihao Zhang, et al.

    The understanding of genetic basis and potential therapeutic targets for metastatic breast cancer (mBC) remains limited. Here we systematically identify the genetic and epigenetic causes underlying breast cancer metastasis from clinically defined alterations through multiplexed CRISPR knockout and base editing screens in various models. Multiple drivers converge on the down-regulation of SMARCA1, a core component of ISWI chromatin-remodeling complexes, to drive metastasis, largely through potentiating TGFβ signaling. Using druggable gene CRISPR screens, we identify SOD1, a key antioxidant enzyme, as a prominent vulnerability in mBC. We further validate the in vivo efficacy of SOD1 pharmacological inhibitor LCS-1 in treating mBC in multiple preclinical models. The exacerbated SOD1 vulnerability in mBC is due to elevated TGFβ signaling which impinges on mitochondrial homeostasis, thereby resulting in superoxide radical overload and subsequently triggering ferroptosis. Together, our work provides a comprehensive landscape on the genetic basis and informs therapeutic interventions for mBC.


  • Open Access

    Systematic decoding of the resistance mechanisms and therapeutic vulnerabilities in TKI-resistant hepatocellular carcinoma

    by Teng Fei, Shixin Ma, You Li, Xiaofeng Wang, Xiaolong Cheng, Zihan Li, Quanhui Dai, Yateng Dong, Huiyin Lu, Lujun Chen, et al.

    Drug resistance to multiple tyrosine kinase inhibitors (TKIs) is a major issue during clinical management of hepatocellular carcinoma (HCC). Here, through multiplexed in vitro and in vivo CRISPR knockout and base editing screens, we elucidate the resistance mechanisms of HCC to typical TKIs (sorafenib, lenvatinib and regorafenib). Multiple genetic or epigenetic alterations can drive resistance to these TKIs through divergent mechanisms. Among them, a tumor cell-intrinsic (rather than tumor microenvironment-driven) extracellular matrix remodeling mechanism stands out across multiple resistance models and clinical samples. Using druggable gene CRISPR knockout screens, we identify proteasome as a prominent and convergent vulnerability of multiple TKI-resistant HCC cells. We further validate the efficacy of clinically available proteasome inhibitor bortezomib in treating TKI-resistant HCC in multiple preclinical models. Mechanistically, increased p21 expression and dysregulated proteolytic machineries in TKI-resistant tumors account for the pronounced sensitivity to bortezomib. Our work not only delineates a comprehensive landscape of drug resistance mechanisms in TKI-treated HCC, but also suggests actionable therapeutics with immediate clinical potential against these tumors.

  • Open Access

    When Retrieval Hurts: A Critical Analysis of RAG in Medical Question Answering

    by Weidong Xie, Yushan Fang, Xinxin Zheng, Dongjun Liu, Zihan Li

    Retrieval-Augmented Generation (RAG) has been widely adopted to enhance Large Language Models (LLMs) by incorporating external knowledge, yet its effectiveness in medical question answering remains underexplored. This study presents a systematic evaluation of RAG systems on the MedQA-USMLE dataset, revealing counterintuitive findings that challenge the "always-RAG" paradigm. We evaluated three RAG approaches (BM25, Dense Retrieval, and Hybrid) against a pure LLM baseline using Qwen3-8B-Instruct as the primary LLM, with a knowledge base of 125,847 medical textbook chunks from 18 authoritative sources. Surprisingly, all RAG methods underperformed the pure LLM baseline (60.69%), with BM25-RAG, Dense-RAG, and Hybrid-RAG achieving 59.43%, 60.14%, and 59.91% accuracy, respectively. Our analysis reveals that RAG introduces a dual effect: while correcting 5-6% of questions, it simultaneously misleads 6-7% of cases, resulting in a net negative impact of 7-16 questions. Critically, we demonstrate that retrieval confidence scores fail to predict RAG utility (AUC ≈ 0.53, Cohen’s d = 0.06), indicating current retrieval systems cannot distinguish helpful from harmful contexts. Oracle analysis suggests a theoretical upper bound improvement of +6.05% if perfect RAG selection were achievable, highlighting the urgent need for selective RAG strategies. These findings challenge the assumption that external knowledge universally improves medical AI systems and emphasize the importance of context-aware retrieval mechanisms for clinical safety.

  • Open Access

    Author Correction: CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

    by Chunge Zhong, Wen-Jie Jiang, Yingjia Yao, Zexu Li, You Li, Shengnan Wang, Xiaofeng Wang, Wenjuan Zhu, Siqi Wu, Jing Wang, et al.

  • Open Access

    CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

    by Chunge Zhong, Wen-Jie Jiang, Yingjia Yao, Zexu Li, You Li, Shengnan Wang, Xiaofeng Wang, Wenjuan Zhu, Siqi Wu, Jing Wang, et al.

    Resistance to chemotherapy has been a major hurdle that limits therapeutic benefits for many types of cancer. Here we systematically identify genetic drivers underlying chemoresistance by performing 30 genome-scale CRISPR knockout screens for seven chemotherapeutic agents in multiple cancer cells. Chemoresistance genes vary between conditions primarily due to distinct genetic background and mechanism of action of drugs, manifesting heterogeneous and multiplexed routes towards chemoresistance. By focusing on oxaliplatin and irinotecan resistance in colorectal cancer, we unravel that evolutionarily distinct chemoresistance can share consensus vulnerabilities identified by 26 second-round CRISPR screens with druggable gene library. We further pinpoint PLK4 as a therapeutic target to overcome oxaliplatin resistance in various models via genetic ablation or pharmacological inhibition, highlighting a single-agent strategy to antagonize evolutionarily distinct chemoresistance. Our study not only provides resources and insights into the molecular basis of chemoresistance, but also proposes potential biomarkers and therapeutic strategies against such resistance.


  • Optimization of fiber reinforced lightweight rubber concrete mix design for 3D printing

    by Baocheng Xiong, Ping Nie, Huanbao Liu, Xiaoxi Li, Zihan Li, Wenyu Jin, Xiang Cheng, Guangming Zheng, Liang Wang


  • Intrinsic targeting of host RNA by Cas13 constrains its utility

    by Zexu Li, Zihan Li, Xiaolong Cheng, Shengnan Wang, Xiaofeng Wang, Shixin Ma, Zhiyan Lu, Han Zhang, Wenchang Zhao, Zhisong Chen, et al.

    Cas13 can be used for the knockdown, editing, imaging or detection of RNA and for RNA-based gene therapy. Here by using RNA immunoprecipitation sequencing, transcriptome profiling, biochemical analysis, high-throughput screening and machine learning, we show that Cas13 can intrinsically target host RNA in mammalian cells through previously unappreciated mechanisms. Different from its known cis/trans RNA-cleavage activity, Cas13 can also cleave host RNA via mechanisms that are transcript-specific, independent of the sequence of CRISPR RNA and dynamically dependent on the conformational state of Cas13, as we show for several Cas13-family effectors encoded in one-vector and two-vector lentiviral systems. Moreover, host genes involved in viral processes and whose transcripts are intrinsically targeted by Cas13 contribute to constraining the lentiviral delivery and expression of Cas13. Our findings offer guidance for the appropriate use of lentiviral Cas13 systems and highlight the need for caution regarding intrinsic RNA targeting in Cas13-based applications.


  • Open Access

    Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches

    by Xiaolong Cheng, Zexu Li, Ruocheng Shan, Zihan Li, Shengnan Wang, Wenchang Zhao, Han Zhang, Lumen Chao, Jian Peng, Teng Fei, et al.

    A major challenge in the application of the CRISPR-Cas13d system is to accurately predict its guide-dependent on-target and off-target effect. Here, we perform CRISPR-Cas13d proliferation screens and design a deep learning model, named DeepCas13, to predict the on-target activity from guide sequences and secondary structures. DeepCas13 outperforms existing methods to predict the efficiency of guides targeting both protein-coding and non-coding RNAs. Guides targeting non-essential genes display off-target viability effects, which are closely related to their on-target efficiencies. Choosing proper negative control guides during normalization mitigates the associated false positives in proliferation screens. We apply DeepCas13 to the guides targeting lncRNAs, and identify lncRNAs that affect cell viability and proliferation in multiple cell lines. The higher prediction accuracy of DeepCas13 over existing methods is extensively confirmed via a secondary CRISPR-Cas13d screen and quantitative RT-PCR experiments. DeepCas13 is freely accessible via http://deepcas13.weililab.org.


  • A chemical-enhanced system for CRISPR-Based nucleic acid detection

    by Zihan Li, Wenchang Zhao, Shixin Ma, Zexu Li, Yingjia Yao, Teng Fei


  • Open Access

    A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses

    by Zexu Li, Yingjia Yao, Xiaolong Cheng, Qing Chen, Wenchang Zhao, Shixin Ma, Zihan Li, Hu Zhou, Wei Li, Teng Fei